Literature DB >> 8938728

Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels.

J S Poling1, M A Rogawski, N Salem, S Vicini.   

Abstract

Anandamide has been identified in porcine brain as an endogenous cannabinoid receptor ligand and is believed to be a counterpart to the psychoactive component of marijuana, delta 9-tetrahydrocannabinol (delta 9-THC). Here we report that anandamide directly inhibits (IC50, 2.7 muM) Shaker-related Kv1.2 K+ channels that are found ubiquitously in the mammalian brain. Delta 9-THC also inhibited Kv1.2 channels with comparable potency (IC50, 2.4 muM), as did several N-acyl-ethanolamides with cannabinoid receptor binding activity. Potassium current inhibition occurred through a pertussis toxin-insensitive mechanism and was not prevented by the cannabinoid receptor antagonist SR141716A. Utilizing excised patches of Kv1.2 channel-rich membrane as a rapid and sensitive bioassay, we found that phospholipase D stimulated the release of an endogenous anandamide-like K+ channel blocker from rat brain slices. Structure-activity studies were consistent with the possibility that the released blocker was either anandamide or another N-acyl-ethanolamide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938728     DOI: 10.1016/0028-3908(96)00130-x

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  27 in total

1.  Functional CB1 cannabinoid receptors in human vascular endothelial cells.

Authors:  J Liu; B Gao; F Mirshahi; A J Sanyal; A D Khanolkar; A Makriyannis; G Kunos
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Extraction (DSX) from Erigeron breviscapus modulates outward potassium currents in rat retinal ganglion cells.

Authors:  Shuo Yin; Zhong-Feng Wang; Jun-Guo Duan; Lu Ji; Xue-Jing Lu
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

4.  Cell-Autonomous Excitation of Midbrain Dopamine Neurons by Endocannabinoid-Dependent Lipid Signaling.

Authors:  Stephanie C Gantz; Bruce P Bean
Journal:  Neuron       Date:  2017-03-02       Impact factor: 17.173

Review 5.  Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System.

Authors:  Shana M Augustin; David M Lovinger
Journal:  ACS Chem Neurosci       Date:  2018-02-19       Impact factor: 4.418

Review 6.  Two-pore potassium channels in the cardiovascular system.

Authors:  Alison Gurney; Boris Manoury
Journal:  Eur Biophys J       Date:  2008-05-01       Impact factor: 1.733

7.  Vascular effects of anandamide and N-acylvanillylamines in the human forearm and skin microcirculation.

Authors:  Pouya Movahed; Vladimir Evilevitch; Tomas L G Andersson; Bo A G Jönsson; Per Wollmer; Peter M Zygmunt; Edward D Högestätt
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

8.  Identification of a pharmacological target for genioglossus reactivation throughout sleep.

Authors:  Kevin P Grace; Stuart W Hughes; Richard L Horner
Journal:  Sleep       Date:  2014-01-01       Impact factor: 5.849

9.  Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex.

Authors:  Grzegorz Godlewski; Manfred Göthert; Barbara Malinowska
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

10.  The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism.

Authors:  Murat Oz; Vanaja Jaligam; Sehamuddin Galadari; George Petroianu; Yaroslav M Shuba; Toni S Shippenberg
Journal:  J Neurochem       Date:  2009-12-24       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.